



# It's in Your Mind: Addiction as a Chronic Brain Disease

**Marvin D. Seppala, MD**  
*Chief Medical Officer*



**Hazelden Betty Ford**  
Foundation

# Addiction is Characterized by:

---

- Compulsion to seek and take the drug
- Loss of control in limiting intake
- Diminished recognition of significant problems
- Emergence of negative emotional state
- Craving
- Chronicity and relapse

# Addiction is a Brain Disease

---

NOT:

- Secondary to another psychiatric illness
- A moral or ethical problem
- A personality disorder
- A choice





# Genetic Vulnerability

---

- Estimated genetic risk 40-60%
- Multiple genes are involved with drug responses
- A few genes have been identified that are protective



# Environmental Risk Factors Consistently Related to Risk of Self Administration

---


- Low socioeconomic class
- Poor parental support
- Drug availability



# Environmental Risk Factors

---

- **Stress** is a common feature among environmental risk factors, both for initiation of use and relapse.
- Co-occurring **psychiatric illness** and a history of **trauma** increase the risk of addiction and of relapse.





"C'mon, Sylvia ... where's your spirit of adventure?"




# The Brain



# The Human Brain – A Detailed Examination



# Brain Reward Center



## Mesolimbic Dopamine System (Median Forebrain Bundle)



# NEURONS & NEUROTRANSMISSION

# “An Irreproducible System”

---

- A human may have 100 billion neurons, with an estimated 100 trillion (100,000,000,000,000) connections
- “*Neuron* and *nerve cell* are synonyms that refer to the major information-conveying cells in the nervous system.”


# The Neuron: Its Four Parts

---

1. Dendrites: “receives signals from other nerve cells and relay them to the cell body”
  - Dendrites can vary from 2 or 3 up to 10,000 in a purkinje cell in the cerebellum, which can have as many as 150,000 connections
2. Cell body: Nucleus with genes of the cell
3. Axon: “carries the message from the cell body”
4. Terminal: “relay the message to the dendrites, cell body, or even terminals of the next cell”



# Neurons (Nerve Cells)



# Signal Conduction

---

- Neurons do not touch each other in conducting a signal from one to the other
- A “synapse, synaptic gap” or “synaptic cleft” exists between them

*This gap is 15-50 nanometers (nm)  
A nanometer is one billionth of a meter  
A million synaptic gap widths added together  
barely total an inch*



# Signal Conduction

---


- Signals are transmitted electrically within the neuron
- But once the signal reaches the synapse, it stops, so a microscopic chemical called a neurotransmitter crosses the synapse
- Neurotransmitters are produced in the neuron, stored in sacs called “vesicles”

# The Most common Neurotransmitters

---

- Acetylcholine
- Norepinephrine
- Epinephrine
- **Dopamine**
- Endorphin
- Enkephalin
- Serotonin
- GABA
- Substance “P”
- Anandamide
- Glycine
- Histamine
- Nitric oxide
- Glutamic acid
- Cortisone

# Message Arrives



Nerve impulse

Presynaptic neuron

Vesicle with neurotransmitters


Reuptake port

Synaptic gap

Receptor site

Postsynaptic neuron

Message Transmitted




Receptor site

Postsynaptic neuron



# The Synapse



# Two Types of Neurotransmitters

---

- “Excitatory” neurotransmitters: augment the potential for signal propagation in the post-synaptic neurons; they increase the likelihood of an electric signal
- “Inhibitory” neurotransmitters, prevent the propagation of the action potential; they decrease the likelihood of an electric signal
- The specificity of a particular neurotransmitter (whether it acts in an excitatory or inhibitory fashion) is normally an inherent property of the neurotransmitter itself.



Dogs and alcohol: the tragic untold story




# **THE NEUROTRANSMITTERS ROLE IN ADDICTION**




# Addictive Drugs Are Associated With Specific Neurotransmitters

Drugs	Neurotransmitter System Action
Alcohol	Facilitates GABA receptor function Inhibits NMDA (Glutamate) receptor function
Marijuana	Agonist at CB <sub>1</sub> and CB <sub>2</sub> cannabinoid receptors
Cocaine	Indirect agonist of dopamine receptors by inhibiting dopamine transporters
Amphetamine	Indirect agonist of dopamine receptors by stimulating dopamine release
Opiates	Agonist at MU, delta and kappa receptors
Nicotine	Agonist at nicotinic acetylcholine receptors


# Normal Dopamine Release



# Dopamine Release Due to Cocaine



# Normal Receptor Function



# Alcohol and Neurotransmitters

---

## **GABA**

- Primary inhibitory neurotransmitter
- Decreases with chronic use

## **Glutamate:**

- Primary excitatory neurotransmitter
- Increases with chronic use

## **Opioids:**

- Alcohol stimulates endorphin release

## **Dopamine:**

- Alcohol stimulates release, directly and via endorphins



# Neuroadaptation (Neuroplasticity)

Repeated exposure



Changes in nuclear function



Altered transcription of target genes  
(abnormal proteins or receptors)



Altered activity of the neuron  
(neurotransmitter dysregulation)




Altered reward circuitry



Altered behavior (Loss of control)

*Lowon*



**"Hey! Look what Zog do!"**



## **ADDICTION: A BRAIN DISEASE**

# **Addiction is a Disorder of...**

- **Incentive salience**
- **Reward deficit**
- **Stress surfeit**
- **Executive function**



# Addiction ≠ Casual Use

---


- Compulsion to seek and take the drug
- Loss of control in limiting intake
- Diminished recognition of significant problems
- Emergence of negative emotional state
- Craving
- Chronicity and relapse

# Acute Intoxication: Primarily Reward Circuitry

---

- A Hedonic activity
- Positive reinforcement
- All drugs of abuse enhance dopamine release
- Mesolimbic dopamine system

# Neurochemical Circuits in Drug Reward (Acute)



Drug	Action	Where
Cocaine/ Amphetamine	Release dopamine by direct action on dopamine terminals	Nucleus Accumbens Amygdala
Opioids	Activate opioid receptors	VTA, Nucleus Accumbens Amygdala
	Facilitate dopamine release	VTA, Nucleus Accumbens
Alcohol	Activates GABA receptors or GABA release	VTA, Nucleus Accumbens Amygdala
	Facilitates release of opioid peptides	VTA, Nucleus Accumbens Amygdala
	Facilitates release of dopamine	Nucleus Accumbens
Nicotine	Activates nicotine acetylcholine receptors	VTA, Nucleus Accumbens Amygdala
Cannabinoids	Activates cannabinoid CB <sub>1</sub> receptors	VTA, Nucleus Accumbens Amygdala
	Facilitates release of dopamine	Nucleus Accumbens



# Establishment of the Addictive Cycle

---

- Positive Reinforcement from the drug diminished
- Negative Reinforcement from the drug increases
- Motivational withdrawal syndrome established
- Incentive salience narrows the individuals focus

# The Addictive Cycle

## Three Stages

The transition to addiction from casual drug use involves the brain areas associated with these three stages


- Binge / Intoxication
- Withdrawal / Negative Affect
- Preoccupation / Anticipation (craving)



# Neural Circuits of the Binge/Intoxication Stage

*Koob GF, Volkow ND.*


*Neuropsychopharmacol Rev, 2010, 35:217-238.*



## Incentive Saliency

- euphoria
- intoxication
- cue learning
- habits

# Neural Circuits of the Withdrawal/Negative Affect Stage




## Negative Affect

- dysphoria
- anxiety
- irritability
- malaise

↓  
Amygdala

↓  
Bed Nucleus of the Stria Terminalls

# Neural Circuits of the Preoccupation/Anticipation “Craving” Stage







# Summary

---

Addiction is a chronic brain disease and the manifestations that we find so puzzling are best understood by examining the neurobiological underpinnings. We can come to understand the behaviors associated with addiction by understanding the brain pathology.

# Resources

---

- Neurocircuitry of Addiction  
Koob, Volkow: Neuropsychopharmacol Reviews (2010) 35, 217-238
- Dynamics of Neuronal Circuits in Addiction  
Koob Pharmacopsychiatry 2009; 42 (Suppl 1): S32
- Neuropathology of Substance Use Disorders  
Cadet, Bisagno, Milroy Acta Neuropathol (2014) 127; 91-107